Funding for this research was provided by:
the Beijing Science and Technology Innovation Medical Development Foundation (KC2021-JX-0186-65)
National Natural Science Foundation of China (82002465, 82203732)
China Postdoctoral Science Foundation (2022M711336)
Fundamental Research Funds for the Central Universities (21622322)
Open Funds of State Key Laboratory of Oncology in South China (HN2022-06)
Received: 14 September 2022
Accepted: 12 December 2022
First Online: 17 December 2022
: The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University. Approval of use of cancer tissues in our study were obtained from the Committee for Ethical Review of Research involving Human Subjects of Sun Yat-sen University.
: All authors have read and approved the manuscript including content and presentation to the clinical epigenetics.
: The authors declare no conflicts of interest.